The GLP-1 Receptor Agonists Market is witnessing growth because of the increasing incidences of Type 2 Diabetes and obesity, the rising need for efficacious weight management solutions, cardioprotective effects, expansion in the areas of clinical use, high acceptance rates of medicines such as Semaglutide, and innovations in the pharma industry
[DOI] [PubMed] [Google Scholar] Associated Data This section collects any data citations, data availability statements, or supplementary materials included in this article
Ease up on the worst offenders
A peer-reviewed study published earlier this March, for instance, found that prescription rates of semaglutide and tirzepatide started rising substantially toward the end of 2022, while rates of bariatric surgery began dramatically declining in 2023
Both medications are effective, but their impacts on your body can differ
What's included: Compounded semaglutide, shipped monthly